Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David V Sheehan

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Expert Review of Neurotherapeutics|August 14, 2009
Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disordersKeming Gao, David V Sheehan, Joseph R Calabrese
Psychopharmacology Bulletin|May 22, 2007
The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B A Raj
Innovations in Clinical Neuroscience|December 19, 2014
Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STS)Darlene M Amado, Darlene A Beamon, David V Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
Status Update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014David V Sheehan, Jennifer M Giddens, Ivan Sascha Sheehan
Psychiatry (Edgmont (Pa. : Township))|September 30, 2010
Generic Conversion of the SSRI Market and the Impact on Branded ProductsElisa F Cascade, Amir H Kalali, David V Sheehan
International Clinical Psychopharmacology|August 4, 2012
Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarateDavid V Sheehan, Julie Locklear, Henrik Svedsäter, et al.
Innovations in Clinical Neuroscience|December 19, 2014
The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?Jennifer M Giddens, Kathy Harnett Sheehan, David V Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical ReviewDavid V Sheehan, Jennifer M Giddens, Kathy Harnett Sheehan
Journal of Affective Disorders|October 19, 2013
Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance studyDavid V Sheehan, Henrik Svedsäter, Julie C Locklear, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|September 17, 2010
Expenditures associated with dose titration at initiation of therapy in patients with major depressive disorder: a retrospective analysis of a large managed care claims databaseFabian Camacho, Meg C Kong, David V Sheehan, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Expert Review of Neurotherapeutics|August 14, 2009
Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disordersKeming Gao, David V Sheehan, Joseph R Calabrese
Psychopharmacology Bulletin|May 22, 2007
The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorderDavid V Sheehan, Kathy Harnett Sheehan, B A Raj
Innovations in Clinical Neuroscience|December 19, 2014
Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STS)Darlene M Amado, Darlene A Beamon, David V Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
Status Update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014David V Sheehan, Jennifer M Giddens, Ivan Sascha Sheehan
Psychiatry (Edgmont (Pa. : Township))|September 30, 2010
Generic Conversion of the SSRI Market and the Impact on Branded ProductsElisa F Cascade, Amir H Kalali, David V Sheehan
International Clinical Psychopharmacology|August 4, 2012
Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarateDavid V Sheehan, Julie Locklear, Henrik Svedsäter, et al.
Innovations in Clinical Neuroscience|December 19, 2014
The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?Jennifer M Giddens, Kathy Harnett Sheehan, David V Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical ReviewDavid V Sheehan, Jennifer M Giddens, Kathy Harnett Sheehan
Journal of Affective Disorders|October 19, 2013
Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance studyDavid V Sheehan, Henrik Svedsäter, Julie C Locklear, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|September 17, 2010
Expenditures associated with dose titration at initiation of therapy in patients with major depressive disorder: a retrospective analysis of a large managed care claims databaseFabian Camacho, Meg C Kong, David V Sheehan, et al.
Pageof 9